Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a … PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ... Jama 320 (10), 984-994, 2018 | 703 | 2018 |
A review of treatment modalities for Middle East Respiratory Syndrome Y Mo, D Fisher Journal of antimicrobial chemotherapy 71 (12), 3340-3350, 2016 | 141 | 2016 |
Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study A Henderson, DL Paterson, MD Chatfield, PA Tambyah, DC Lye, PP De, ... Clinical Infectious Diseases 73 (11), e3842-e3850, 2021 | 137 | 2021 |
Using machine learning to guide targeted and locally-tailored empiric antibiotic prescribing in a children's hospital in Cambodia M Oonsivilai, Y Mo, N Luangasanatip, Y Lubell, T Miliya, P Tan, L Loeuk, ... Wellcome open research 3, 131, 2018 | 81 | 2018 |
Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and … PNA Harris, NL Ben Zakour, LW Roberts, AM Wailan, HM Zowawi, ... Journal of Antimicrobial Chemotherapy 73 (3), 634-642, 2018 | 81 | 2018 |
Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia … PNA Harris, M Yin, R Jureen, J Chew, J Ali, S Paynter, DL Paterson, ... Antimicrobial resistance and infection control 4, 1-10, 2015 | 79 | 2015 |
A meta‐analysis of the association between Helicobacter pylori (H. pylori) infection and hyperemesis gravidarum QX Ng, N Venkatanarayanan, MLZQ De Deyn, CYX Ho, Y Mo, WS Yeo Helicobacter 23 (1), e12455, 2018 | 74 | 2018 |
Transmission of community-and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study Y Mo, DW Eyre, SF Lumley, TM Walker, RH Shaw, D O’Donnell, L Butcher, ... PLoS medicine 18 (10), e1003816, 2021 | 69 | 2021 |
Non-adherence in non-inferiority trials: pitfalls and recommendations Y Mo, C Lim, JA Watson, NJ White, BS Cooper bmj 370, 2020 | 60 | 2020 |
Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). 2018. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality … PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ... Jama 320 (10), 984-994, 0 | 57 | |
The contribution of hospital-acquired infections to the COVID-19 epidemic in England in the first half of 2020 GM Knight, TM Pham, J Stimson, S Funk, Y Jafari, D Pople, S Evans, ... BMC infectious diseases 22 (1), 556, 2022 | 51 | 2022 |
A systematic review of the use of rifaximin for Clostridium difficile infections QX Ng, W Loke, NX Foo, Y Mo, WS Yeo, AYS Soh Anaerobe 55, 35-39, 2019 | 42 | 2019 |
Atypical hand, foot, and mouth disease: eczema coxsackium can also occur in adults PNA Harris, AD Wang, M Yin, CK Lee, S Archuleta The Lancet Infectious Diseases 14 (11), 1043, 2014 | 38 | 2014 |
The burden and dynamics of hospital-acquired SARS-CoV-2 in England BS Cooper, S Evans, Y Jafari, TM Pham, Y Mo, C Lim, MG Pritchard, ... Nature 623 (7985), 132-138, 2023 | 36 | 2023 |
Zika virus—a review for clinicians Y Mo, BM Alferez Salada, PA Tambyah British medical bulletin 119 (1), 25-36, 2016 | 30 | 2016 |
Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: A modelling study and meta-analysis Y Mo, M Oonsivilai, C Lim, R Niehus, BS Cooper PLoS medicine 20 (6), e1004013, 2023 | 29 | 2023 |
Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance R Niehus, E van Kleef, Y Mo, A Turlej-Rogacka, C Lammens, Y Carmeli, ... Elife 9, e49206, 2020 | 28 | 2020 |
Relating knowledge, attitude and practice of antibiotic use to extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage: results of a cross-sectional community survey Y Mo, I Seah, PSP Lye, XLJ Kee, KYM Wong, KKK Ko, RTH Ong, ... BMJ open 9 (3), e023859, 2019 | 24 | 2019 |
Duration of carbapenemase-producing Enterobacteriaceae carriage in hospital patients Y Mo, A Hernandez-Koutoucheva, P Musicha, D Bertrand, D Lye, OT Ng, ... Emerging infectious diseases 26 (9), 2182, 2020 | 22 | 2020 |
Optimising trial designs to identify appropriate antibiotic treatment durations KB Pouwels, M Yin, CC Butler, BS Cooper, S Wordsworth, AS Walker, ... BMC medicine 17, 1-7, 2019 | 21 | 2019 |